Ensayos clínicos A continuación se enumeran ensayos clínicos actuales.10 estudios en Centro de Cáncer de Cabeza y Cuello (estudios abiertos únicamente). Filtrar esta lista de estudios según la ubicación, el estado del estudio y más. Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies Scottsdale/Phoenix, Ariz. The purpose of this study is to assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma. Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck Rochester, Minn. This randomized phase II/III trial studies how well radiation therapy works when given together with cisplatin compared to docetaxel or cetuximab and docetaxel after surgery in treating patients with stage III-IV squamous cell head and neck cancer. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or transmit tumor killing molecules to them. It is not yet known whether radiation therapy is more effective when given with cisplatin, docetaxel, or cetuximab and docetaxel. Effect of Agent Orange Exposure on Endocrine Tumor Aggressiveness Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz. The intent is to collect relevant clinical data on patients exposed to Agent Orange plus assessment of the tissue for genetic mutations known to be associated with growth of thyroid cancer and pituitary tumors and report our findings as a descriptive case series. A Study of the Impact of the Terminology Used to Identify Papillary Thyroid Cancer on the Treatment Options Chosen by Patients Rochester, Minn. The purpose of this study is to explore how using different terms (with or without the word cancer) to identify papillary thyroid cancer might affect the decisions patients would make about treatment. A Study to Identify Biomarkers in the Blood, Saliva or Tissue for Oropharyngeal Squamous Cell Cancer Rochester, Minn. The purpose of this study is to identify a biomarker (or biomarkers) that is present when disease is present (i.e., at diagnosis or recurrence) and not present when disease is absent (i.e., after treatment, in HPV negative patients or in normal controls). Gemini Study to Evaluate the Integration of Cancer Genetic Testing into a Cancer Clinical Practice at Mayo Clinic at Arizona Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to determine the prevalence of genetic mutations in cancer patients from various ethnic populations seeking care at Mayo Clinic cancer clinics. BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate the feasibility of molecular characterization based on tumor mutational burden (TMB) for participant stratification, as assessed by the proportion of participants with less than or equal to a 21-day turnaround time for biopsy results in Stage I of the study. Also, to evaluate the feasibility of molecular characterization based on TMB and gene expression profiling (GEP) (for TIS - tumor inflammation signature) for stratification in the overall study (Stage I and Stage II). Additinoally, to evaluate the effectiveness by overall response rate (ORR – defined as confirmed and unconfirmed partial responses plus complete responses) of cabozantinib plus nivolumab in each disease cohort, both across and within tumor biomarker subgroups. In-home Versus In-Clinic Subcutaneous Nivolumab Administration through Connected and Remote Cancer CARE Beyond Walls Jacksonville, Fla. The purpose of this study is to evaluate the impact of the location of SQ Nivo administration, at the infusion center or in the home, on patient preference and acceptability, safety, patient reported outcomes (PROs), and clinical outcomes. A Study to Develop a Biorepository of Blood Samples from Cancer Patients Participating in the Gemini (IRB 19-006717) Protocol Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to develop a biorepository of blood samples from cancer patients participating in the Gemini (IRB 19-006717) protocol. These samples will be used for future biomarker discovery and other translational studies. A Study to Evaluate Pemetrexed and Pembrolizumab to Treat Recurrent and/or Metastatic Salivary Gland Malignancies Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla. The purpose of this study is to determine the response rate of the combination of Pemetrexed and Pembrolizumab in patients with recurrent or metastatic salivary gland cancer (R/M SGC). A continuación se enumeran ensayos clínicos actuales.10 estudios en Centro de Cáncer de Cabeza y Cuello (estudios abiertos únicamente). Filtrar esta lista de estudios según la ubicación, el estado del estudio y más. Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies Scottsdale/Phoenix, Ariz. The purpose of this study is to assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma. Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck Rochester, Minn. This randomized phase II/III trial studies how well radiation therapy works when given together with cisplatin compared to docetaxel or cetuximab and docetaxel after surgery in treating patients with stage III-IV squamous cell head and neck cancer. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or transmit tumor killing molecules to them. It is not yet known whether radiation therapy is more effective when given with cisplatin, docetaxel, or cetuximab and docetaxel. Effect of Agent Orange Exposure on Endocrine Tumor Aggressiveness Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz. The intent is to collect relevant clinical data on patients exposed to Agent Orange plus assessment of the tissue for genetic mutations known to be associated with growth of thyroid cancer and pituitary tumors and report our findings as a descriptive case series. A Study of the Impact of the Terminology Used to Identify Papillary Thyroid Cancer on the Treatment Options Chosen by Patients Rochester, Minn. The purpose of this study is to explore how using different terms (with or without the word cancer) to identify papillary thyroid cancer might affect the decisions patients would make about treatment. A Study to Identify Biomarkers in the Blood, Saliva or Tissue for Oropharyngeal Squamous Cell Cancer Rochester, Minn. The purpose of this study is to identify a biomarker (or biomarkers) that is present when disease is present (i.e., at diagnosis or recurrence) and not present when disease is absent (i.e., after treatment, in HPV negative patients or in normal controls). Gemini Study to Evaluate the Integration of Cancer Genetic Testing into a Cancer Clinical Practice at Mayo Clinic at Arizona Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to determine the prevalence of genetic mutations in cancer patients from various ethnic populations seeking care at Mayo Clinic cancer clinics. BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate the feasibility of molecular characterization based on tumor mutational burden (TMB) for participant stratification, as assessed by the proportion of participants with less than or equal to a 21-day turnaround time for biopsy results in Stage I of the study. Also, to evaluate the feasibility of molecular characterization based on TMB and gene expression profiling (GEP) (for TIS - tumor inflammation signature) for stratification in the overall study (Stage I and Stage II). Additinoally, to evaluate the effectiveness by overall response rate (ORR – defined as confirmed and unconfirmed partial responses plus complete responses) of cabozantinib plus nivolumab in each disease cohort, both across and within tumor biomarker subgroups. In-home Versus In-Clinic Subcutaneous Nivolumab Administration through Connected and Remote Cancer CARE Beyond Walls Jacksonville, Fla. The purpose of this study is to evaluate the impact of the location of SQ Nivo administration, at the infusion center or in the home, on patient preference and acceptability, safety, patient reported outcomes (PROs), and clinical outcomes. A Study to Develop a Biorepository of Blood Samples from Cancer Patients Participating in the Gemini (IRB 19-006717) Protocol Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to develop a biorepository of blood samples from cancer patients participating in the Gemini (IRB 19-006717) protocol. These samples will be used for future biomarker discovery and other translational studies. A Study to Evaluate Pemetrexed and Pembrolizumab to Treat Recurrent and/or Metastatic Salivary Gland Malignancies Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla. The purpose of this study is to determine the response rate of the combination of Pemetrexed and Pembrolizumab in patients with recurrent or metastatic salivary gland cancer (R/M SGC). Solicite una consulta Pericia & clasificacionesInvestigación Dec. 31, 2024 Comparte en: FacebookTwitter Centro de Cáncer de Cabeza y CuelloPágina inicialdel departamentoSeccionesPanorama generalAnálisis y procedimientosEnfermedades que se tratanMédicosMédicos por sede y especialidadGrupos especializadosPericia & clasificacionesEnsayos clínicosInvestigaciónCostos & seguro médicoRemisiones Investigación: los pacientes son la prioridad Mostrar la transcripción Para video Investigación: los pacientes son la prioridad [SUENA MÚSICA] Dr. Joseph Sirven, profesor de Neurología, Mayo Clinic: La misión de Mayo se centra en el paciente. La prioridad es el paciente. Aquí, la misión y la investigación se hacen para progresar en la forma de ayudar mejor al paciente y para asegurarnos de que el paciente sea la prioridad en la atención médica. De muchas maneras, esto equivale a un ciclo. Puede comenzar con algo tan simple como una idea que se desarrolla en un laboratorio, se traslada a la atención directa del paciente y, si todo sale bien y resulta útil o beneficioso, pasa a ser el método estándar. Creo que una de las características tan singulares de la forma de investigar en Mayo es la concentración en el paciente, y es lo que realmente le ayuda a captar la atención de todos. SeccionesSolicite una ConsultaPanorama generalAnálisis y procedimientosEnfermedades que se tratanMédicosMédicos por sede y especialidadGrupos especializadosPericia & clasificacionesEnsayos clínicosInvestigaciónCostos & seguro médicoRemisiones ORG-20456033 Centros y departamentos médicos Centro de Cáncer de Cabeza y Cuello